SMi’s ADC Summit 2013 has returned and will be held on the 20th to 21st May. This year’s event will present a unique insight into latest technological and scientific developments and will be the perfect platform for debate and problem-solving discussion as well as an in-depth view into novel innovations, developments and utilities of antibody-drug conjugates that will see world-renowned expert speakers from Immunogen, UCB, Bayer, MedImmune, Spirogen and Genentec.
SMi is pleased to confirm John Hartley, Head of Biology of Spirogen as one of the speakers of the upcoming event.
He will address the design and development of Antibody-Pyrrolobenzodiazepine Conjugates (PBD), advantages and disadvantages of PBD as ADC warheads and there will be a case study discussing the issues of moving forward. Delegates will be given a comprehensive overview of the latest developments in payload delivery and linker strategies, Formulation developments in ADC, recent clinical developments and novel linker strategies.
For the full conference programme and further information please visit http://www.smi-online.co.uk/goto/adcsummit22.asp or contact Fateja Begum on +44 0 207 827 6184 or email [email protected]
About SMi Group
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit http://www.smi-online.co.uk